Want to see GB:COG full AI Analyst Report?
COG Stock Chart & Stats
28.00 p
-0.58 p(-1.49%)
At close: 4:00 PM EST
28.00 p
-0.58 p(-1.49%)
Day’s Range― - ―
52-Week Range23.90 p - 45.00 p
Previous CloseN/A
Volume352.00
Average Volume (3M)32.00K
Market Cap
£17.27M
Enterprise Value16.03M
Total Cash (Recent Filing)£1.13M
Total Debt (Recent Filing)£873.00K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding54,037,327
10 Day Avg. Volume24,264
30 Day Avg. Volume32,004
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£72.00Price Target Upside157.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£11.61M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsStrong gross margins (~74–81%) indicate favorable unit economics and pricing power for the company’s digital cognitive tests. Over a 2–6 month horizon this margin strength supports sustainability of core product profitability and gives scope for operating leverage if revenue stabilises and operating costs are contained.
Improved Balance Sheet / Lower LeverageMaterial reduction in leverage and stronger equity (debt down, equity up to £2.99m) meaningfully lowers refinancing and liquidity risk. Over months this improves resilience to trial-cycle volatility, increases optionality for strategic investment or partnership activity, and reduces near-term solvency pressure.
Recurring, Services-driven Revenue ModelA revenue mix of licensing/usage fees plus project and support services to pharma/CROs creates recurring, contract-backed revenue tied to long drug-development cycles. Structurally this yields sticky customer relationships and predictable demand patterns, supporting durable revenue streams if the company retains study clients.
Bears Say
Multi-year Operating And Net LossesSustained operating and net losses across 2022–2025 erode retained earnings and shareholder value. Over the medium term this constrains reinvestment into sales, product development, and commercial expansion, increases reliance on external financing, and raises execution risk until a credible path to sustained profitability is delivered.
Declining Revenue TrendA clear top-line decline from £13.5m (2023) to £9.4m (2025) reduces the company’s ability to fully exploit its high gross margins. Over 2–6 months persistent revenue contraction pressures operating leverage, highlights potential client attrition or lower trial volumes, and makes margin recovery and scale more difficult without new business wins.
Negative Cash Generation HistoryThe shift from positive operating/free cash flow in 2020–2022 to sizeable cash burn in 2023–2025 means the business is not self-funding. Continued negative cash flow necessitates external financing, limits capacity to invest in growth or product development, and elevates financial vulnerability despite improvements in burn by 2025.
Cambridge Cognition Holdings News
COG FAQ
What was Cambridge Cognition Holdings Plc’s price range in the past 12 months?
Cambridge Cognition Holdings Plc lowest share price was 23.90 p and its highest was 45.00 p in the past 12 months.
What is Cambridge Cognition Holdings Plc’s market cap?
Cambridge Cognition Holdings Plc’s market cap is £17.27M.
When is Cambridge Cognition Holdings Plc’s upcoming earnings report date?
Cambridge Cognition Holdings Plc’s upcoming earnings report date is Sep 29, 2026 which is in 69 days.
How were Cambridge Cognition Holdings Plc’s earnings last quarter?
Cambridge Cognition Holdings Plc released its earnings results on Apr 13, 2026. The company reported -0.015 p earnings per share for the quarter, missing the consensus estimate of -0.006 p by -0.009 p.
Is Cambridge Cognition Holdings Plc overvalued?
According to Wall Street analysts Cambridge Cognition Holdings Plc’s price is currently Undervalued.
Does Cambridge Cognition Holdings Plc pay dividends?
Cambridge Cognition Holdings Plc does not currently pay dividends.
What is Cambridge Cognition Holdings Plc’s EPS estimate?
Cambridge Cognition Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cambridge Cognition Holdings Plc have?
Cambridge Cognition Holdings Plc has 54,037,327 shares outstanding.
What happened to Cambridge Cognition Holdings Plc’s price movement after its last earnings report?
Cambridge Cognition Holdings Plc reported an EPS of -0.015 p in its last earnings report, missing expectations of -0.006 p. Following the earnings report the stock price went down -1.282%.
Which hedge fund is a major shareholder of Cambridge Cognition Holdings Plc?
Currently, no hedge funds are holding shares in GB:COG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
COG Stock 12 Month Forecast
Average Price Target
72.00 p
▲(157.14% Upside)